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Atrial fibrillation (AF) can be managed with rhythm- or rate-control strategies. There are few
data from routine clinical practice on the frequency with which each strategy is used and
their correlates in terms of patients’ clinical characteristics, AF control, and symptom
burden.
Methods
RealiseAF was an international, cross-sectional, observational survey of 11,198 patients
with AF. The aim of this analysis was to describe patient profiles and symptoms according
to the AF management strategy used. A multivariate logistic regression identified factors
associated with AF management strategy at the end of the visit.
Results
Among 10,497 eligible patients, 53.7% used a rate-control strategy, compared with 34.5%
who used a rhythm-control strategy. In 11.8% of patients, no clear strategy was stated. The
proportion of patients with AF-related symptoms (EHRA Class > = II) was 78.1% (n = 4396/
5630) for those using a rate-control strategy vs. 67.8% for those using a rhythm-control
strategy (p<0.001). Multivariate logistic regression analysis revealed that age <75 years or
the paroxysmal or persistent form of AF favored the choice of a rhythm-control strategy. A
change in strategy was infrequent, even in patients with European Heart Rhythm Associa-
tion (EHRA) Class > = II.
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Conclusions
In the RealiseAF routine clinical practice survey, rate control was more commonly used
than rhythm control, and a change in strategy was uncommon, even in symptomatic
patients. In almost 12% of patients, no clear strategy was stated. Physician awareness
regarding optimal management strategies for AF may be improved.
Introduction
Atrial fibrillation (AF) is associated with increased mortality and morbidity, including stroke,
heart failure, and impaired quality of life [1]. Despite these potential consequences, whether it
is better to restore and maintain sinus rhythm (rhythm-control strategy) or allow AF to con-
tinue while controlling ventricular rate (rate-control strategy) remains uncertain, since clinical
trials have not demonstrated clear superiority of either strategy [2,3].
While randomized clinical trials represent the highest level of evidence, patient populations
recruited for clinical trials are highly selective and might not be truly representative of routine
clinical practice. In particular, they are often derived from largely Western European and
North American settings and may not reflect the variety of clinical manifestations and manage-
ment strategies.
Surveys and registries provide complementary data on AF management strategies in clinical
practice. Most of the previous information either originates from a single country [4,5], Europe
[6], or North America [7], or excludes patients with permanent AF [8]. RealiseAF was a recent,
large-scale, international, cross-sectional observational survey of patients with all types (almost
half with the permanent form) of AF, encompassing Europe, Asia, North Africa, the Middle
East, and Latin America [1]. As such, RealiseAF provides a unique opportunity to examine the




The design and methods of this survey have been previously published [1]. RealiseAF was an
international, cross-sectional, observational survey of 11,198 patients with AF registered at 831
sites in 26 countries from October 2009 to May 2010. Participating countries were Algeria,
Azerbaijan, Belgium, Bulgaria, Czech Republic, Egypt, Germany, Hungary, India, Ireland,
Italy, Lebanon, Lithuania, Mexico, Morocco, Portugal, Russia, Slovakia, Spain, Sweden, Swit-
zerland, Taiwan, Tunisia, Turkey, Ukraine, and Venezuela.
Objectives
The primary objectives of this sub-analysis were to (i) describe patients’ characteristics accord-
ing to AF management strategy prior to the visit; (ii) assess the control of AF and AF-related
symptoms according to AF management strategy prior to the visit; (iii) determine the predic-
tors for the selection of AF management strategy at the end of the visit; and (iv) analyze the
modification of AF management strategy (overall, and according to control of AF and Euro-
pean Heart Rhythm Association [EHRA] class on the day of the visit).
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Patients
Patients with a history of AF (treated or not, and independent of the rhythm at the time of
inclusion), with> = 1 AF episode (documented by standard electrocardiogram [ECG] or by
Holter ECG in the previous 12 months) or documented current AF, who provided written
informed consent, were enrolled. Exclusion criteria were limited to mental disability (such as
dementia or significant cognitive disorders), post-operative AF within 3 months of cardiac sur-
gery, and participation in clinical trials investigating AF or antithrombotics in the previous
month.
Selection of investigators
Participating physicians were randomly selected from a global list of cardiologists and inter-
nists (office- and hospital-based) in each country. To remove any bias, the ratio of recruited
cardiologists to internists was predetermined to reflect the practice in each country; the list and
ratio were validated by national coordinators. In order to maximize recruitment of consecutive
patients, the maximum duration of enrollment per center was short (6 weeks). Each investiga-
tor was asked to recruit a minimum of 10 patients and a maximum of 30.
Patient assessment, including AF strategy and control
Data were collected on patient demographics, cardiovascular risk factors (arterial hypertension,
dyslipidemia, diabetes mellitus, obesity, family history of premature cardiovascular disease/
sudden death, smoking status, and amount of physical activity) and comorbidities (heart fail-
ure, coronary artery disease, cerebrovascular disease, peripheral arterial disease, and valvular
heart disease), left ventricular ejection fraction measurement within the last 12 months, type of
AF, AF management strategy prior to and at the end of the visit. Investigators could choose
either rate or rhythm strategy based on their judgement. If no specific strategy was undertaken,
"none" (no determined strategy) should be chosen. AF control was defined electrocardiographi-
cally as being in sinus rhythm or being in AF with a resting ventricular rate80 beats per min-
ute [bpm] at the time of visit on resting ECG). The New York Heart Association (NYHA)
classification of heart failure and EHRA (for arrhythmia-related symptoms) classification [9]
were used by the investigators to categorize symptoms.
Statistical analysis
The details of the determination of sample size have been described previously [1]. Population
characteristics were summarized as mean and standard deviation for continuous variables and
as count and percentages for qualitative variables. Descriptive data were described according to
the AF management strategy used prior to and at the end of the visit. Comparisons between
subgroups (rhythm-control vs. rate-control strategies) were made using either the χ2 test, Fish-
er’s exact test for nominal variables, or analysis of variance for quantitative variables. The
change in AF management strategy at the end of the visit was also described according to AF
control and EHRA classification on day of visit.
To identify factors associated with the choice of AF management strategy at the end of the
visit (rhythm-control rather than rate-control strategy), a multivariate stepwise logistic regres-
sion (with a significance level of 20% for entering and 5% for retaining the variables in the
model) was performed. Variables included age (by class); sex; obesity (body mass index
[BMI]> = 30 kg/m2); physical activity; smoking status; EHRA AF cardiac symptoms classifica-
tion; time since first AF diagnosis (by class); type of AF; and history of heart failure (by NYHA
class), valvular heart disease, hypertension, cerebrovascular disease, coronary artery disease,
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diabetes, dyslipidemia, peripheral arterial disease, and hyperthyroidism. Discrimination
between models was assessed using c-statistics and calibrated using Hosmer–Lemeshow χ2 sta-
tistics. The odds ratios and associated 95% confidence intervals (CIs) for choosing a rhythm-
control strategy rather than a rate-control strategy were determined; the multivariate analysis
was adjusted for country. Analyses were performed using SAS1 statistical software, version 9.2
(SAS Institute, Cary, NC, USA).
Results
Patient characteristics according to AF management strategy prior to the
visit
From October 2009 to May 2010, 831 sites were active in screening 11,198 patients [1]. Overall,
10,497 patients were eligible for analysis (Table 1). Of these, 3626 (34.5%) managed AF with a
Table 1. Patient characteristics according to AFmanagement strategy prior to the visit.
Rhythm-control Strategy (n = 3626) Rate-control Strategy (n = 5642) No strategy(n = 1223) p-valuea
Age in years, mean (SD) 64.8 (11.9) 68.0 (11.9) 65.7 (13.5) <0.001
> = 75 years, % 21.4 32.5 27.3 <0.001
Male, % 56.4 55.8 58.9 0.52
Type of AF, % <0.001
Paroxysmal 48.9 8.7 28.4
Persistent 33.6 15.4 20.7
Permanent 12.1 72.6 26.8
First episode 5.3 3.3 24.1
Time since ﬁrst AF diagnosis <0.001
<3 months 21.5 12.6 55.0
3–6 months 8.9 5.0 4.7
6–12 months 13.6 8.4 7.9
> = 12 months 56.1 74.0 32.4
Cardiovascular risk factors and comorbidities
Hypertension 74.5 72.0 66.0 0.007
CHADS2 score > = 2 52.3 66.2 51.0 <0.001
Obesity (BMI > = 30 kg/m2) 34.0 32.6 29.5 0.16
Heart failure <0.001
No heart failure or NYHA I 69.0 52.0 70.3
NYHA II 21.6 28.8 17.4
NYHA III or IV 9.4 19.2 12.3
Left ventricular ejection fraction <0.001
<35% 4.4 8.2 5.8
35–50 14.4 22.4 17.4
> = 50% 81.3 69.4 76.8
Coronary artery disease 29.1 35.2 28.5 <0.001
Cerebrovascular disease 10.8 16.8 11.3 <0.001
Peripheral arterial disease 3.5 5.6 3.1 <0.001
Valvular heart disease 17.8 33.7 20.8 <0.001
aRhythm vs. rate-control strategy.
AF, atrial ﬁbrillation; BMI, body mass index; CHADS2, Cardiac failure, hypertension, age > = 75 years, diabetes, prior stroke [doubled]; NYHA, New York
Heart Association; SD, standard deviation.
doi:10.1371/journal.pone.0147536.t001
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rhythm-control strategy prior to the visit, 5642 (53.7%) with a rate-control strategy, 1223
(11.7%) with no determined strategy, and 6 (<0.1%) with both strategies. The 6 patients using
both strategies were not included in the analyses. The distribution of management strategy for
each participating country in the study is shown in Table in S1 Table. Patients using a rhythm-
control strategy were younger, with 21.4% aged> = 75 years (vs. 32.5% and 27.3% in those
using a rate- control strategy or no strategy, respectively). For those patients using a rhythm-
control strategy, 48.9%, 33.6%, and 12.1% of patients had paroxysmal, persistent, or permanent
AF, respectively. In comparison, for those patients using a rate-control strategy, 8.7%, 15.4%,
and 72.6% of patients had paroxysmal, persistent, or permanent AF, respectively. Correspond-
ing numbers for patients with no strategy were in-between those of patients using a rhythm-
control strategy and those of patients using a rate-control strategy. The time since first
diagnosis of AF was more likely to have occurred 12 months previously for patients using a
rate-control strategy (74.0%) than for those using a rhythm-control strategy (56.1%) or no
strategy (32.4%).
Cardiovascular risk factors and comorbidities according to AF
management strategy prior to the visit
In patients using a rate-control or a rhythm-control strategy prior to the visit, the proportion
with hypertension (74.5% and 72.0%, respectively) and with obesity (34.0% and 32.6%, respec-
tively) was similar. However, more patients using a rate-control than a rhythm-control strategy
had coronary artery disease (35.2% vs. 29.1%, respectively), cerebrovascular disease (16.8% vs.
10.8%, respectively) or valvular heart disease (33.7% vs. 17.8%, respectively) (Table 1). Patients
with more severe heart failure (NYHA III or IV) were more likely to be using a rate-control
than a rhythm-control strategy (19.2% vs. 9.4%, respectively), while those with no heart fail-
ure/NYHA I were more likely to be using a rhythm-control than a rate-control strategy (69.0%
vs. 52.0%, respectively) (Table 1).
AF control and symptoms according to AF management strategy prior to
visit
Fig 1A shows control of AF (assessed on the day of the visit) according to the AF management
strategy used prior to the visit. Control of AF was evaluable in 91.8% (n = 9634/10,491) of the
total population. In patients using a rhythm-control strategy (34.7%; n = 3340/9634), 74.2%
were in sinus rhythm or in AF with a heart rate80 bpm on a resting ECG. In comparison, in
patients managed with a rate-control strategy (53.7%; n = 5178/9634), only 51.6% were in
sinus rhythm or in AF with a heart rate< = 80 bpm on a resting ECG. A total of 11.6%
(n = 1116/9634) were not using any clearly identified strategy, but 48.6% (n = 543/1116) of
these had AF control.
Fig 1B shows EHRA symptom classification during the visit according to prior AF manage-
ment strategy; these data were evaluable in 99.7% (n = 10,463/10,491) of patients. The propor-
tion with AF-related symptoms (EHRA Class> = II) was 67.8% (n = 2452/3617) in patients
using a rhythm-control strategy prior to the visit vs. 78.1% (n = 4396/5630) in patients using a
rate-control strategy prior to the visit.
Predictive factors for the choice of AF management strategy at end of
visit
Based on the findings of the multivariate logistic regression analysis, after adjustment by coun-
try, independent predictors for choosing a rhythm-control strategy were paroxysmal AF,
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persistent AF, or age<75 years. Independent predictors for choosing a rate-control strategy
were permanent AF; uncontrolled AF (vs. being in sinus rhythm); AF with heart rate< = 80
bpm (vs. being in sinus rhythm); or having cerebrovascular disease, diabetes, hyperthyroidism,
valvular heart disease, or symptomatic heart failure (Fig 2).
Change in AF management strategy at end of visit
Changes in AF management strategy were relatively infrequent in the AF patients surveyed.
Among patients with controlled and uncontrolled AF, 14.0% and 21.8% of patients, respec-
tively, had a change in management strategy at the end of the visit (15.1% among patients in
sinus rhythm and 13.1% among patients in AF with a heart rate< = 80 bpm) (Table 2). A
change in AF management strategy was more frequent for symptomatic patients (EHRA
Class> = II) than for those without any symptoms (EHRA Class I) (17.5% vs. 14.8%, respec-
tively). Similarly, for patients with uncontrolled AF, a change in management strategy was
more frequent for symptomatic patients (EHRA Class> = II) than for those without any
symptoms (EHRA Class I) (22.1% vs. 20.3%, respectively), and the change from no specific
Fig 1. (A) AF control (at visit) and (B) AF symptoms (EHRA) (at visit) according to AFmanagement strategy prior to the visit. p<0.001 (AF control);
p<0.001 (AF symptoms). AF, atrial fibrillation; bpm, beats per minute; EHRA, European Heart Rhythm Association.
doi:10.1371/journal.pone.0147536.g001
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strategy to an AF management strategy was more frequent in symptomatic patients (EHRA
Class> = II; 58.3%) (Table 2). Among the 468 patients with no determined strategy, uncon-
trolled AF and symptoms (EHRA Class> = 2), 11.3% remained in this undetermined strategy
at the end of the visit.
Patient characteristics according to the AF management strategy at end
of visit
At the end of the visit, 3909 (37.2%), 6036 (57.5%), and 533 (5.1%) patients were using a
rhythm-control, rate-control, or no strategy, respectively (Table 3). Patients using a rhythm-
control strategy at the end of the visit were younger, with only 20.4% aged> = 75 years. A
greater proportion of these patients had paroxysmal AF (49.3%) than either persistent (33.4%)
or permanent (9.0%) AF. In comparison, a greater proportion of patients using a rate-control
strategy had permanent AF (71.2%) than either paroxysmal (8.5%) or persistent (15.3%) AF.
Fig 2. Multivariate logistic regression analysis: independent predictors for choice of management strategy at the end of the visit (rhythm-control
strategy vs. rate-control strategy). AF, atrial fibrillation; BMI, body mass index; bpm, beats per minute; CI, confidence interval; EHRA, European Heart
Rhythm Association; HF, heart failure; HR, heart rhythm; OR, odds ratio.
doi:10.1371/journal.pone.0147536.g002
Table 2. Change (%) in AFmanagement strategy at the end of the visit.












AF controlled (n = 5704) 14.0 36.8 22.9 23.7 16.5
AF not controlled (n = 3961) 21.8 57.2 23.1 16.4 3.4
Sinus rhythm (n = 2559) 15.1 38.6 15.8 24.4 21.2
In AF with HR 80 bpm (n = 3145) 13.1 35.2 29.6 23.1 12.1
EHRA I (n = 2740) 14.8 42.6 23.6 21.7 12.1
EHRA II (n = 7751) 17.5 48.9 22.8 19.6 8.7
AF not controlled, EHRA I (n = 706) 20.3 52.4 26.6 18.2 2.8
AF not controlled, EHRA > = II
(n = 3245)
22.1 58.3 22.2 16.0 3.5
AF, atrial ﬁbrillation; bpm, beats per minute; EHRA, European Heart Rhythm Association; HR, heart rate.
doi:10.1371/journal.pone.0147536.t002
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Cardiovascular risk factors and comorbidities according to AF
management strategy at end of visit
The pattern of cardiovascular risk factors and comorbidities according to AF management
strategy at the end of the visit was consistent with that prior to the visit. For example, the pro-
portion of patients with hypertension or obesity remained similar both within and between
groups, and more patients using a rate-control strategy had coronary artery disease, cerebro-
vascular disease, or valvular heart disease (Table 3).
AFmanagement strategy at end of visit according to AF control and
symptoms
A total of 9621 patients assessed for AF control had data related to AF management at the end
of the visit. For patients who were in sinus rhythm as assessed during the visit, the majority
(81.2%; n = 2074/2553) were using a rhythm-control strategy at the end of the visit. Conversely,
Table 3. Patient characteristics according to AFmanagement strategy at the end of the visit.
Rhythm-control Strategy (n = 3909) Rate-control Strategy (n = 6036) p-valuea
Age in years, mean (SD) 64.5 (11.9) 68.0 (12.0) <0.001
> = 75 years, % 20.4 32.5 <0.001
Male, % 57.3 55.1 0.03




Unable to assign because ﬁrst episode 8.2 5.0
Time since ﬁrst AF diagnosis <0.001
<3 months 28.2 15.3
3–6 months 8.5 4.8
6–12 months 12.7 8.3
>12 months 50.6 71.7
Hypertension 72.9 72.2 0.48
CHADS2 score > = 2 50.5 66.2 <0.001
Obesity (BMI > = 30 kg/m2) 33.0 32.9 0.85
Diabetes mellitus 18.2 23.7 <0.001
Heart failure <0.001
No heart failure or NYHA I 70.0 52.2
NYHA II 20.8 28.5
NYHA III or IV 9.2 19.2
Left ventricular ejection fraction <0.001
<35% 4.3 8.3
35–50 14.8 22.0
> = 50% 80.8 69.7
Coronary artery disease 29.0 34.9 <0.001
Cerebrovascular disease 10.1 16.6 <0.001
Peripheral arterial disease 3.1 5.6 <0.001
Valvular heart disease 16.5 33.3 <0.001
aRhythm-control vs. rate-control strategy.
AF, atrial ﬁbrillation; BMI, body mass index; CHADS2, Cardiac failure, hypertension, age 75 years, diabetes, prior stroke [doubled]; NYHA, New York
Heart Association; SD, standard deviation.
doi:10.1371/journal.pone.0147536.t003
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for patients who were in AF with a heart rate80 bpm as assessed during the visit, the majority
(78.0%; n = 2446/3135) were using a rate-control strategy at the end of the visit. Similarly, for
patients with uncontrolled AF as assessed during the visit, 71.5% (n = 2814/3933) were using a
rate-control strategy at the end of the visit (Fig 3A).
In patients with AF-related symptoms (EHRA Class> = II) as assessed during the visit, (Fig
3B), the majority were using a rate-control strategy (61.2%; n = 4719/7716) rather than a rhythm-
control strategy (34.7%; n = 2676/7716) or no strategy (4.2%; n = 321/7716) at the end of the visit.
Discussion
The major finding of this international cross-sectional survey is that a rate-control strategy
appears to be used more commonly than a rhythm-control strategy for AF in a routine clinical
practice setting. Another important finding is that physicians did not clearly select either strat-
egy for AF management in 11.7% of patients. Patients using a rate-control strategy were gener-
ally older; more symptomatic; and more likely to have coronary artery, cerebrovascular, or
valvular heart disease than those who used a rhythm-control strategy.
Interestingly, far more patients in the present survey used a rate-control strategy than in the
previous Euro Heart Survey (54% vs. 27%, respectively) [10]. This is due to several factors:
Fig 3. AFmanagement strategy at end of visit according to (A) AF control (at visit) and (B) AF symptoms (EHRA) (at visit). p<0.001 (AF control);
p<0.001 (AF symptoms). AF, atrial fibrillation; bpm, beats per minute; EHRA, European Heart Rhythm Association.
doi:10.1371/journal.pone.0147536.g003
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Compared with the Euro Heart Survey, the present survey had a larger proportion of patients
with permanent AF, included many countries outside of Europe, and randomly selected the
participating physicians, thereby providing a more generalizable picture of AF management.
To date, clinical trials and meta-analyses have been unable to demonstrate outcome benefits
from a rhythm-control strategy [2,11,12]. For example, in the Atrial Fibrillation Follow-up
Investigation of RhythmManagement (AFFIRM) trial, the percentage of patients requiring
hospitalization was significantly lower in patients using a rate-control strategy than those using
a rhythm-control strategy (p<0.001) as was the incidence of torsade de pointes (p = 0.007) [2].
For patients with heart failure in particular, the pre-specified subgroup analysis of the AFFIRM
study did not support the use of rhythm-control strategy [2]. In the AF-CHF trial enrolling
patients with AF and heart failure, a routine strategy of rhythm control did not reduce the rate
of death from CV cause and worsening of heart failure, as compared with a rate-control strat-
egy [11]. In terms of stroke prevention in the AFFIRM study, the rhythm-control strategy
resulted in numerically more patients suffering from ischemic stroke [2]. In a meta-analysis of
rhythm control vs rate control strategy, the proportion of patients experiencing an ischemic
stroke was similar between the rate-control and rhythm-control groups [13].
There is some evidence in favor of a rhythm-control strategy in some observational studies
[14,15,16], and in post-hoc analyses of the AFFIRM trial, in which patients who were main-
tained in sinus rhythm had better survival rates [17]. In addition, in the REgistry on Cardiac
rhythm disORDers assessing the control of Atrial Fibrillation (RECORD-AF) registry [18], the
use of an early rhythm-control strategy was associated with a lower risk of AF progression.
European and US practice guidelines recommend an initial rate-control strategy for patients
with minimal or no symptoms [19,20]. In the present survey, among asymptomatic patients
(EHRA I), the majority (47.7%) were managed with a rate-control strategy; however, a similar
proportion (44.6%) were managed with a rhythm-control strategy. This suggests that many
patients with AF are not being treated in a fashion consistent with the guidelines.
Our multivariate logistic regression analysis that elicited the independent predictors for
choice of management strategy confirmed prior observations [21,22] that a rhythm-control
strategy was generally used in patients who were younger (<75 years) or had paroxysmal or
persistent AF; whereas the presence of structural heart disease, or comorbidities such as diabe-
tes or hyperthyroidism, were better correlated with use of a rate-control strategy.
In this cross-sectional survey, changes in management strategy were infrequent although, as
would be expected, they were slightly more common in symptomatic patients and in those
with uncontrolled AF. The majority of patients with symptomatic (82.5%), uncontrolled
(78.2%) or symptomatic uncontrolled (77.9%) AF did not undergo a change in management
strategy. Among the 468 patients with no determined strategy, uncontrolled AF and symptoms
(EHRA Class> = 2), 11.3% remained in this undetermined strategy at the end of the visit.
These findings may reflect medical inertia, as well as lingering uncertainties regarding the opti-
mal management strategy for each patient.
Limitations
The present report should be interpreted cautiously, given its observational and cross-sectional
nature. Patients were not randomly assigned to different strategies. Despite the wide geo-
graphic scope of this study, it does not include Central Africa or the United States and Canada,
where there might be major differences in patient characteristics and preferred management
strategies. Additionally, there is a sizeable group of patients for whom no clear strategy was
chosen by the treating physician, reflecting the need for further clarification and education on
AF management.
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Frequency of attack of AF may impact on the strategy which was undertaken. But in the
daily practice, this might not necessarily be true, and other clinical characteristics, including
symptoms, should be considered. The inclusion criteria in this study was the same as that in
the EURO Heart Survey [10] and the RECORD-AF registry [8]. Neither of these 2 studies
could provide information regarding the frequency of AF and management strategy. Instead of
studying the impact of frequency of episodes on management strategy, the main purpose of
this study was to show the correlates of strategy with patients' clinical characteristics, AF con-
trol, and symptom burden in routine clinical practice. Future studies which contain more com-
prehensive description of AF burden before entering may be needed to answer this question.
The choice of a specific resting heart rate to define adequate rate control is somewhat arbi-
trary. Previous AF guidelines defined adequate resting heart rate control as 60 to 80 bpm [23],
and a rate of<80 bpm was used by the AFFIRM study investigators [2]. Thus, 80 bpm was
chosen as the protocol definition of “controlled” AF in the present survey [1].
In conclusion, in the RealiseAF survey reflecting routine clinical practice, a rate-control
strategy was most frequently used, especially in patients with cardiovascular comorbidities. A
change in the management strategy of AF patients appears to be uncommon in clinical prac-
tice, suggesting that awareness among physicians regarding optimal management strategies for
AF could be improved.
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